• Braveheart Bio’s third-quarter 2026 net loss narrowed 55% year over year to $26.5 million.
• Operating expenses fell 49% year over year to $30.15 million.
• Cash, cash equivalents and investments totaled $503.5 million at September 30, 2026, with funding expected to last into 2029.
• LIONHEART-HCM Phase 3 is enrolling patients, with interim results expected in the second half of 2027.
• NOBLEHEART-HCM Phase 3 and fixed-dose TRUEHEART-HCM Phase 2b remain scheduled to begin in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Braveheart Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611101603PRIMZONEFULLFEED9874819) on November 10, 2026, and is solely responsible for the information contained therein.